Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06724562 · ClinicalTrials.gov registry record
IL1 Inhibition in FOP
A clinical trial of Fibrodysplasia Ossificans Progressiva (FOP), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 11
- Enrollment target
- 1
- Study location
NCT06724562: Recruiting study of Fibrodysplasia Ossificans Progressiva (FOP), sponsored by University of California, San Francisco.
NCT06724562 is a study of Fibrodysplasia Ossificans Progressiva (FOP) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06724562, a study of Fibrodysplasia Ossificans Progressiva (FOP), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II study. This study specifically focuses on patients with severe FOP who are being considered by their medical team for rescue therapy with anti-IL1 therapy. Preliminary data suggests patients experience significant decreases in flare frequency when taking anti-IL1 therapy, but other measures of efficacy remain unassessed, such as changes in heterotopic ossification formation, changes in pain medication use, and changes in functionality.
Primary Outcome
Surveys will be used to track the number of clinical flares that a patient experiences before and during treatment with anti-IL1 therapy.
Conditions Studied
Interventions
- OTHER Anti-IL1 Therapy
Study Locations (1)
California
- UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-03 |
What NCT06724562 shows while recruiting
NCT06724562 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva (FOP) appearing as the primary indexed condition, and to 1 intervention - of which Anti-IL1 Therapy is the first listed.
NCT06724562 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06724562 about?
NCT06724562 is a clinical study titled "IL1 Inhibition in FOP". This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and preliminary data that are needed to design a future Phase II...
What is the current status of trial NCT06724562?
This trial is currently recruiting. The enrollment target is 11 participants. The study started on 2025-04-01. Estimated completion is 2027-03.
What conditions does trial NCT06724562 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva (FOP).
What interventions are being tested in trial NCT06724562?
The interventions under investigation include: Anti-IL1 Therapy (OTHER).
Who is sponsoring clinical trial NCT06724562?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06724562 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva (FOP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
RECRUITING · Phase 2
-
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI